Generation of two human induced pluripotent stem cell lines from peripheral blood mononuclear cells of clozapine-tolerant and clozapine-induced myocarditis patients with treatment-resistant schizophrenia

Stem Cell Res. 2022 Aug:63:102877. doi: 10.1016/j.scr.2022.102877. Epub 2022 Jul 28.

Abstract

Clozapine has superior efficacy in the treatment of refractory schizophrenia; however, use of clozapine is limited due to severe side effects, including myocarditis. Using non-integrative Sendai virus, we generated induced pluripotent stem cell lines from peripheral blood mononuclear cells of two patients with refractory schizophrenia, one clozapine-tolerant and one clozapine-induced myocarditis. Both cell lines exhibited a normal karyotype and pluripotency was validated by flow cytometry, immunofluorescence and their ability to differentiate into the three germ layers. These lines can be used to generate 2D and 3D patient-specific human cellular models to identify the mechanism by which clozapine induces myocardial inflammation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antipsychotic Agents* / adverse effects
  • Cell Differentiation
  • Clozapine* / adverse effects
  • Humans
  • Induced Pluripotent Stem Cells* / metabolism
  • Leukocytes, Mononuclear / metabolism
  • Myocarditis* / chemically induced
  • Schizophrenia* / drug therapy
  • Schizophrenia* / metabolism
  • Schizophrenia, Treatment-Resistant

Substances

  • Antipsychotic Agents
  • Clozapine